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Abstract
Background. The percentage of hypochromic red blood
cells (RBCs) (%HYPO) has been demonstrated as
the best predictor of response to iron loading in
haemodialysis patients treated with recombinant
human erythropoietin (rHuEPO). However, we have
previously shown that this parameter is positively
influenced by erythropoietic activity since reticulocytes
are considered hypochromic by cell counters. New
cell counters are able to determine cell volume and
haemoglobin (Hb) concentration separately on
reticulocytes and mature erythrocytes. The aim of
this study was to assess the sensitivity and specificity of
mature erythrocyte parameters in detecting functional
iron deficiency (FID).
Methods. A total of 32 stable chronic haemodialysis
patients in the maintenance phase of rHuEPO therapy
were included. Classical parameters of iron monitoring
and mature erythrocyte parameters were measured
after a 4-week iron-free period. Patients were classified
as responders (R) or non-responders (NR) to an iron
load of 100mg iron sucrose at each dialysis session
for 4 weeks, according to whether their Hb increased
by >1 g/dl at the end of iron loading.
Results. Twelve patients were identified as responders.
Receiver operating characteristic (ROC) curve analysis
demonstrated %HYPO and its corresponding para-
meter on mature erythrocyte, %HYPOm, as the best
predictors of FID. The other parameters were ordered
as follows: tranferrin saturation (TSAT), ferritin
(FRT), mature RBC Hb content (CHm), mean
corpuscular Hb concentration (MCHC), percentage
of mature erythrocytes with a low CHm (%lowCHm),
mean content in Hb (MCH) and reticulocyte Hb
content CHr. Comparing the parameters at different
cut-offs, the best sensitivity, specificity and efficiency
were demonstrated for %HYPOm> 6%.
Conclusion. The best efficiency to predict FID was
found for %HYPOm> 6%. The predictive value of
%HYPO was quite similar. The clinical impact
of %HYPOm in iron monitoring should also be
tested in the induction phase of rHuEPO treatment
because of its independence from erythropoietic
activity.
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hypochromic red blood cells
Introduction
The treatment of renal anaemia with recombinant
human erythropoietin (rHuEPO) has consistently
improved the quality of life and outcome of
haemodialysis patients [1–4]. The efficacy of this
therapy depends in part on the identification and
correction of resistance factors such as vitamin
deficiency, inflammation or hyperparathyroidism.
The major cause of resistance to rHuEPO is iron
deficiency. Absolute iron deficiency is easy to detect.
However, functional iron deficiency, defined as a
positive response to further iron supplementation in
the absence of absolute iron deficiency, remains a
daily challenge for nephrologists. It is not only of
pharmaco-economical but also of clinical importance
since inappropriate intravenous iron administration
can lead to acute and long-term complications. First,
anaphylactic reactions have been described following
intravenous iron administration, mainly associated to
iron dextran [5,6]. Second, the demonstration of
in vitro and in vivo oxidation of lipids and proteins
could lead to oxidative damage [7–9]. However, the
clinical significance of oxidative stress remains
uncertain. Finally, an increased risk of infection has
been suggested to be associated to iron overload
and iron administration [10,11]. Nevertheless, Hoen
et al. [12], in a prospective study, demonstrated that
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the risk of bacteriemia was neither associated with
ferritin level, nor with iron administration.
Routine parameters usually measured for iron
monitoring, such as ferritin (FRT), transferrin satura-
tion (TSAT) or serum iron (SI) have shown low
sensitivity and specificity in the prediction of
response to intravenous iron supplementation in the
haemodialysis population under rHuEPO therapy. The
percentage of hypochromic red blood cells (%HYPO)
has been demonstrated as the most sensitive and
specific parameter for functional iron deficiency [13].
However, %HYPO is positively correlated to the
erythropoietic activity, as reflected by the reticulocyte
count and soluble transferrin receptors (sTfRs) [14].
Indeed, an increased %HYPO following erythropoietic
stimulation with rHuEPO may partly be due to
increased erythrocyte volume (MCV) with a stable
haemoglobin (Hb) content (CH), in a younger
erythroid population, resulting in a decrease in mean
Hb concentration (CHCM) [15]. Usually, rHuEPO
therapy produces both increased erythropoietic activity
and functional iron deficiency, two mechanisms
resulting in elevated %HYPO.
An ideal marker of functional iron deficiency should
thus be independent of the erythropoietic activity, the
influence of which could be minimized through the
measurement of mature erythrocyte parameters,
without the confounding effect of reticulocytes. The
Advia 120 cell counter (Bayer Diagnostics, Tarrytown,
NY, USA) is capable, in addition to providing routine
parameters measured on the whole red cell population,
to separate mature erythrocytes from reticulocytes and
to measure cell volume and haemoglobin concentra-
tion of each individual cell in these two distinct
populations.
The aim of this study was to assess the sensitivity
and specificity of mature erythrocyte parameters and




A total of 32 patients with end-stage renal disease (ESRD)
were included in the study. Of these 13 were females and 19
were males. Mean age was 65 18 years. The origin of ESRD
was diabetes in seven, hypertension in seven, glomerulopathy
in seven, tubulo-interstitial disease in six and other origins in
five. All patients were chronically haemodialysed three times
a week for 3.5 or 4 h. They were all treated with rHuEPO for
at least 3 months and were in the maintenance phase of their
rHuEPO treatment with stable rHuEPO doses for at least
4 weeks. Prior to the study, iron supplementation was
administered in order to meet the recommendations of the
European Best Practice Guidelines (EBPG; FRT> 100 ng/ml
and %HYPO< 10%). Exclusion criteria were adult domi-
nant polycystic kidney disease, malignancy, haemoglobino-
pathy, evidence for chronic or acute bleeding, blood
transfusion in the previous 3 months, hyperparathyroidism
[parathyroid hormone (PTH)> 500 ng/ml], vitamin B12
or folate deficiency, chronic or acute inflammation
[C-reactive protein (CRP)> 30mg/l].
Study design
Patients were screened on the basis of inclusion and exclusion
criteria. The screening period continued for 4 weeks after the
first screening visit, during which time neither rHuEPO
treatment nor iron supplementation were modified. Patients
in whom Hb levels varied by more than 1 g/dl during this
4-week period were excluded from the study.
The study began at the end of the screening period with a
4-week iron washout period. At the end of the iron-free
period, haematologic and iron monitoring parameters were
measured: Hb, haematocrit (Hct), reticulocytes (retic),
%HYPO, reticulocyte Hb content (CHr), mature erythrocyte
Hb content (CHm), percentage of hypochromic mature
erythrocytes (%HYPOm), percentage of mature erythrocytes
with a low Hb content (%lowCHm), mean content in Hb
(MCH), mean corpuscular Hb concentration (MCHC),
FRT, TSAT and sTfRs. Patients in whom Hb levels
increased by more than 1 g/dl during the iron-free period
were excluded from the study.
During the second part of the study, an iron load was
administered to all patients. They received a total dose of
1200mg iron sucrose, administered intravenously at the dose
of 100mg at the end of each dialysis session during 4 weeks.
Haematological parameters were followed weekly during the
whole study. The dose of rHuEPO remained unchanged
during the whole study period.
Patients were classified into responders (R; presumably
functionally iron deficient) and non-responders
(NR; presumably iron replete) according to whether their
Hb increased by more or less than 1 g/dl during the 4-week
iron-loading period.
The protocol was approved by the Ethics Committee of
the University Hospital of Lie`ge. An informed consent was
obtained from each patient included in the study.
Laboratory analyses
Red cell parameters were measured with the Advia 120
cell counter (Bayer Diagnostics, Tarrytown, NY, USA).
Reticulocytes are stained with oxazine 750 and
oxazine-negative cells are identified as mature erythrocytes.
Routine parameters are measured in the pooled population
of reticulocytes and mature erythrocytes (Hb, Hct, MCH,
MCHC). In addition, the cell counter derives in the
two populations separately, the Hb content (CH), as
well as the percentages of microcytic cells
(%micro: cell volume< 60 fl), macrocytic cells (%macro:
cell volume> 120 fl), hypochromic cells (%HYPO: Hb
concentration< 28 pg/ml), hyperchromic cells (%HYPER:
Hb concentration> 41 pg/ml), cells with low CH (%low CH:
Hb content< 27 pg) and cells with high CH (%high CH: Hb
content> 31 pg).
The coefficient of variation (CV) was computed from
replicate measures of patient samples (intra-run CV, n¼ 8)
for %HYPO, %HYPOm, CHr, CHm and %low CH.
All parameters showed excellent reproducibility, with
CVs< 5%. (Table 1)
Serum FRT and sTfRs (QuantikineTM IVDTM,
R&D Systems, Minneapolis, MN, USA) were measured
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by enzyme-linked immunosorbent assays. CRP was
measured using a nephelometric method, serum iron with
a ferrozin method and transferrin with an immuno-
turbidimetric method.
Statistical methods
In the text, values are expressed as mean standard
deviation (M SD). For more readability in the graphs,
values are shown as mean standard error of the mean
(M SEM). Comparisons between groups were performed
using Student’s t tests. P-values< 0.05 were considered as
statistically significant. ROC curve analyses were performed
with MedCalc (Mariakerke, Belgium). The Kappa coeffi-
cients for sensitivity (ksens), specificity (kspec) and efficiency
(keff) were calculated to calibrate these results to prevalence
and level of the test. Kappa coefficients were calculated as
follows: (ksens)¼ (SEQ)/Q0; (kspec)¼ (SP –Q0)/Q and
(keff)¼ (EFFPQP0Q0)/(1PQP0Q0), where P is the
prevalence of the disease in the studied population,
P0 ¼ 1P, Q is the level of the test (percentage of false
positive) and Q0 ¼ 1Q. SE is the sensitivity, SP the
specificity and EFF the efficiency of the test.
Results
Table 2 shows baseline haematological and iron
parameters after the iron washout period. Among the
32 patients, 12 (37.5%) were defined as responders
(functionally iron deficient). Responders had
significantly lower Hb, FRT, TSAT, CHr, CHm
and significantly higher %HYPO, %HYPOm and
%lowCHm. Reticulocyte count was significantly
higher in responders. After iron loading, Hb levels
remained constant (12.9 0.8 vs 12.9 0.7 g/dl) in NR
(iron replete), but increased significantly from
11.7 0.9 to 12.9 1.1 g/dl in R to become similar to
those of NR. The rHuEPO doses were not significantly
different between the groups. However, R tended to
require higher doses than NR (189 129 vs 118 75
UI/kg/week; NS).
Figure 1 summarizes the evolution of the studied
parameters along the 8 weeks of follow-up. In
responders, FRT levels, already lower than in non-
responders at baseline, further decreased significantly
after the iron-free period (248 162 vs 417 249 ng/
ml; P< 0.01). This was accompanied by a significant
decrease of TSAT from 18.8 3.7 to 16.2 3.5%;
P< 0.05). During this period of time, %HYPO,
%HYPOm, CHr, CHm, MCH and MCHC remained
constant. Only %lowCHm increased significantly
(26.4 16.1 vs 23.6 14.1%; P< 0.03). In the same
group of patients, after iron loading, FRT and TSAT
increased significantly (773 381 vs 248 162 ng/ml,
P< 0.001; and 23.9 6.8 vs 16.2 3.5%, P< 0.001,
respectively). CHr increased significantly from
31.2 2.3 to 34.1 2.0; (P< 0.05), while %HYPO
(8.6 6.2 vs 14.1 6.5%; P< 0.001) and %HYPOm
(8.6 5.9 vs 12.9 6.5%; P< 0.001) decreased signifi-
cantly. MCH increased significantly (31.2 2.4 vs
30.1 2.3 pg; P< 0.001). MCHC and CHm did not
change significantly. %lowCHm increased during the
iron-free period (26.4 16.1 vs 23.6 14.1%; P< 0.05)
but decreased in the iron-loading period (18.0 11.6 vs
26.4 16.1%; P< 0.05). Its level at the end of the
follow-up was lower than at the start of the study
(26.4 14.1%) despite its increase during the iron-free
period.
In iron-replete patients, during the washout
period, TSAT, as well as %HYPO, %HYPOm,
CHm, MCH and %lowCHm, remained constant.
The only significantly different parameters were FRT
(446 146 vs 524 148 ng/ml; P< 0.001), CHr
(33.4 1.3 vs 31.9 2.3 pg; P< 0.05) and MCHC
(32.5 0.8 vs 32.1 0.9 pg/ml; P< 0.05). After iron-
loading, FRT (987 250 vs 446 146; P< 0.001),
TSAT (33.5 8.0 vs 25.6 6.6; P< 0.001), MCH
(32.6 1.9 vs 31.9 1.7 pg/ml; P< 0.01) and CHr
(34.7 1.5 vs 33.4 1.3; P< 0.001) increased
significantly, %HYPO decreased significantly
(3.3 1.8 vs 4.5 2.5; P< 0.05), while MCHC, CHm,
%HYPOm and %lowCHm remained constant.
The results of ROC curve analyses are shown in
Figure 2. All studied parameters had an area under the
curve (AUC) significantly >0.5. Their discriminative
abilities to predict functional iron deficiency were, in
this order: sTfR (AUC: 0.989; SE: 0.034), %HYPO
(AUC: 0.937; SE: 0.051), %HYPOm (AUC:0.935;
SE:0.052), TSAT (AUC: 0.896; SE: 0.060), FRT
(AUC: 0.834; SE: 0.076), CHm (AUC: 0.808; SE:
0.076), MCHC (AUC: 0.804; SE: 0.077), %lowCHm
(AUC: 0.792; SE: 0.088), MCH (AUC: 0.723; SE:0.090)
Table 2. Parameters as measured at the end of the iron-free period
before iron loading (baseline)
NR R P
Hb (g/dl) 12.9 0.7 11.7 0.9 <0.001
Hct (%) 39.7 2.1 37.8 3.3 0.06
Retic (%) 1.6 0.4 2.1 0.5 <0.01
Retic abs (103/mm3) 64.6 19.1 85.1 17.2 <0.01
CHr (pg) 33.4 1.3 31.2 2.3 <0.01
CHm (pg) 31.9 1.2 30.0 2.3 <0.01
%LowCHm (%) 11.3 4.5 26.4 16.1 <0.001
%HYPO (%) 4.5 2.5 14.1 6.5 <0.001
%HYPOm (%) 3.9 2.4 12.9 6.5 <0.001
FRT (ng/ml) 446 146 248 162 <0.01
TSAT (%) 25.6 6.6 16.2 3.5 <0.001
rHuEPO dose (UI/kg/wk) 118 75 189 129 NS
Table 1. Reproducibility of measure for the Advia parameters.
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Fig. 1. Evolution of the studied parameters during the study. Comparisons are shown between end of screening period and baseline and
between baseline and end of iron-loading period. Responders (R) and non-responders (NR) are depicted separately. *P< 0.05; **P< 0.01.
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and CHr (AUC: 0.752; SE: 0.086). However, there were
no statistically significant differences between any of
these parameters.
The best threshold values for prediction of iron
response, calculated by ROC curve analysis, were
>6.6mg/l for sTfR,> 7.3% for %HYPO,> 6.8% for
%HYPOm,< 21% for TSAT,< 400 ng/ml
for FRT,< 32.4 pg for CHm,< 31.3 pg/ml for
MCHC,> 19% for %lowCHm,< 29.5 pg for MCH
and <30 pg for CHr.
We calculated the specificity, sensitivity and effi-
ciency of these various tests at different cut-offs, as well
as combinations thereof as proposed by the European
and American guidelines. [16,17] These results are
shown in Table 3, where parameters are classified
following the best calibrated efficiency (keff).
%HYPOm> 6% was the best predictor of response
to iron loading. At this threshold, %HYPOm was able
to correctly classify 87.5% of the cases. The efficiency
of criteria proposed by the European Best Practice
Guidelines (EBPG) [16] (FRT< 100 ng/ml or
%HYPO> 10%) was similar, with correct classifica-
tion in 85.7% of the cases. Parameters recommended
by the DOQI guidelines [17] (FRT< 100 ng/ml or
TSAT< 20%) were a little less efficient with a correct
classification in 78.6% of the cases.
Discussion
Stimulation of erythropoiesis with rHuEPO leads to a
rapid decrease of FRT, TSAT and CHr and
a subsequent increase of %HYPO [15,18,19], a pattern
highly suggestive of functional iron deficiency.
Nutrition is the source of 1–2mg iron a day in
normal subjects. This source of iron is far insufficient
to meet the requirements of a stimulated bone marrow.
Furthermore, oral iron absorption is impaired in
patients suffering from chronic and ESRD [20] and
still more so when phosphate binders are used.
Intravenous iron supplementation has proven much
higher efficacy for this purpose [21] and is now widely
prescribed. However, iron administration and iron
overload can bear negative consequences. Intravenous
iron administration has been shown to induce lipid [10]
and protein [11] oxidation. Moreover, iron overload
may lead to direct organ damage [21] and an increased
risk of infection [7,8], but this association remains
controversial. For all these reasons, assessment of iron
requirements and monitoring of iron therapy require
accurate markers.
Current European [16] and American [17] guidelines
may not be optimal for the detection of functional iron
deficiency. In a previous prospective trial [23], iron
supplements were increased in an unselected cohort of
haemodialysis patients. Data suggested that response
to rHuEPO continues to improve when one targets
the normal range for %HYPO (<2.5%) and that
such an approach was cost-effective. FRT levels
required to achieve lower %HYPO values were much
greater than the current recommended range.
Unfortunately, this could produce a significant
degree of iron overload.
Tessitore et al. [13], in a study similar to ours,
demonstrated that the best single predictor of func-
tional iron deficiency was %HYPO and that the
Fig. 2. Results of the ROC curves. AUC, area under the curve; SE, standard error; BCO, best cut-off.
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threshold for that diagnosis was 6%, lower than the
10% currently recommended. Moreover, the sensitivity
and specificity of TSAT and FRT in that study were
much lower. Even though the value of %HYPO is well
established, we have shown in previous studies that
erythropoietic activity positively influenced %HYPO
[14,24] and that %HYPO could be just increased due
to the production of a younger population of
erythrocytes with an increased cell volume and a
normal Hb content, thereby leading to a decreased Hb
concentration in this cell population that includes
reticulocytes [15].
In this study, ROC curve analyses confirmed the
value of several parameters for functional iron
deficiency. In these analyses, sTfR had the largest
AUC, directly followed by %HYPO and %HYPOm.
However, the sensitivity, specificity and efficiency
could not be estimated for sTfR since results were
available in only five iron-deficient patients.
In addition, despite its possible discriminative value,
sTfR assays are not available everywhere and the cost
associated to its measurement is much higher
compared with that of red cell parameter
determination that is part of CBC.
In the order of decreasing AUC, TSAT came after
hypochromy with a good sensitivity (90.9%) but quite
a low specificity (70.6%). The specificity of FRT
levels< 100 ng/ml was perfect. However, its sensitivity
was unacceptable from a clinical point of view.
Actually, at that threshold, only about 25% of
iron-deficient patients could be identified. From the
ROC curve analyses, the best threshold for FRT was
400 ng/ml. At such a high cut-off, the sensitivity,
specificity and efficiency were similar to those of
%HYPO> 6%.
Parameters based on the Hb content of mature
erythrocytes, CHm and %lowCHm, could have been
of interest since, excluding the effect of reticulocytosis,
they further exclude volume variations associated with
the younger age of the erythrocyte population resulting
from a stimulated erythropoiesis. However, their
sensitivity, specificity and efficiency were lower than
that for %HYPOm. The efficiency of calculated
parameters on the global population (MCH and
MCHC) was very low (75 and 62.5%, respectively),
much lower than EBPG and DOQI guidelines and
usual parameters of the iron monitoring. They thus do
not provide any further information or advantage.
This is probably due to the ‘dilution’ of hypochromic
cells by the majority of the normochromic erythrocyte
population. In this point of view, the %HYPO
presents the advantage to detect hypochromic erythro-
cytes as soon as they leave the bone marrow.
%HYPOm and %HYPO are then the more early
markers of iron deficiency.
Despite their similar AUC, %HYPO and
%HYPOm showed slight differences in terms of
efficiency for the intended purpose, but they were not
statistically significant. We believe that the stability of
the patients in the steady state of the treatment
of anaemia is, at least in part, responsible for the
non-significance of these differences. The best
efficiency was found for %HYPOm at a cut-off
value> 6%. At that threshold, 87.5% of the patients
were correctly classified as iron deficient or iron
replete according to the defined criteria.
Table 3. Sensitivity, specificity and efficiency of the studied iron parameters at different thresholds. Cut-off values were chosen from ROC
curves as well as levels currently recommended in the literature. Parameters are ordered by efficiency
Parameter Sensitivity (%) ksens (%) Specificity (%) kspec (%) Efficiency (%) keff (%)
%HYPOm> 6% 91.7 85.2 85.0 65.7 87.5 74.2
FRT< 100 ng/ml or %HYPOm> 6% 90.9 84.3 85.0 64.2 87.1 72.9
FRT< 100 ng/ml or %HYPO> 10% 72.7 59.8 94.1 81.6 85.7 69.0
%HYPO> 10% 66.7 53.7 95.0 82.2 84.4 65.0
FRT< 400 ng/ml 90.9 81.8 76.5 53.0 82.1 64.2
%lowCHm> 20% 58.3 46.6 100.0 100.0 84.4 63.7
%HYPO> 6% 91.7 83.4 75.0 50.0 81.3 62.6
TSAT< 20% 90.9 80.4 70.6 45.1 78.6 57.8
FRT< 100 ng/ml or TSAT< 20% 90.9 80.4 70.6 45.1 78.6 57.8
CHm< 30 pg 50.0 38.5 100.0 100.0 81.3 55.7
%HYPOm> 10% 50.0 36.0 95.0 77.1 78.1 49.0
%HYPO> 4% 100.0 100.0 50.0 27.3 68.8 42.9
%HYPOm> 4% 91.7 77.9 55.0 28.0 68.8 41.3
%lowCHm> 15% 66.7 43.9 75.0 38.5 71.8 40.8
MCH< 29.5 pg 42.0 7.2 95.0 86.7 75.0 40.7
CHm< 29 pg 33.3 23.8 100.0 100.0 75.0 38.5
CHr< 30 pg 33.3 23.8 100.0 100.0 75.0 38.5
FRT< 100 ng/ml 27.3 18.6 100.0 100.0 71.4 31.2
CHm< 31 pg 66.7 37.3 65.0 25.3 65.5 30.1
CHr< 29 pg 25.0 17.2 100.0 100.0 71.8 29.2
MCHC< 31.3 pg/ml 75.0 42.9 55.0 20.0 62.5 27.3
%lowCHm> 10% 91.7 70.5 40.0 16.5 59.4 26.8
TSAT< 30% 100.0 100.0 29.4 14.1 57.1 24.6
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Therefore, %HYPOm slightly improves the detection
of iron-deficient patients compared with the combina-
tion of FRT< 100 ng/ml and %HYPO> 10% [16] or
FRT< 100 ng/ml and TSAT< 20% [17]. However,
these differences were not statistically significant.
In this study, in spite of stability during the
maintenance phase of rHuEPO treatment, about one-
third of the patients improved their Hb levels with iron
supplementation. This observation underlines the fact
that functional iron deficiency remains underdiag-
nosed. Correct diagnosis and treatment could lead to
rHuEPO dose sparing and cost saving in anaemia
management.
Mature erythrocyte parameters, in particular
%HYPOm, appear to be at least as efficient as
%HYPO for iron monitoring. As this study was
performed in a perfect steady state of anaemia therapy,
erythropoietic activity was quite low as demonstrated
by low reticulocyte counts. The induction phase of
rHuEPO treatment represents a much stronger ery-
thropoietic stimulation and an increased ratio between
young and old erythrocyte that could further increase
the efficiency of %HYPOm compared with %HYPO,
but this remains to be studied.
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